Jonathan R. Strosberg, MD

Dr. Jonathan Strosberg is an associate professor at H. Lee Moffitt Cancer Center, specializing in management of gastrointestinal and neuroendocrine malignancies. He is a graduate of Harvard University and Cornell University Medical College, and completed his residency and fellowship training programs at Georgetown University Hospital and H. Lee Moffitt Cancer Center. He leads the neuroendocrine tumor division at Moffitt and heads the gastrointestinal department research program. He also serves as chair of the scientific review committee. Dr. Strosberg has published over eighty articles on the diagnosis and management of neuroendocrine malignancies in the Lancet, Journal of Clinical Oncology, Annals of Oncology, Annals of Surgery, Cancer, and other major journals, and has written twelve articles for UptoDate. He is a recipient of the National Cancer Institute’s Clinical Investigator Team Leadership Award. He serves on the board of directors of the North American Neuroendocrine Tumor Society (NANETS), on the neuroendocrine guidelines committee of the National Comprehensive Cancer Network (NCCN), and on the neuroendocrine task force of the National Cancer Institute (NCI) and the neuroendocrine staging committee of the American Joint Committee on Cancer (AJCC).  

Provider

Jonathan R. Strosberg, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Gastrointestinal Oncology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Hematology
  • Medical Oncology
FELLOWSHIP:
  • H. Lee Moffitt Cancer Center & Research Institute - Medical Oncology & Hematology
RESIDENCY:
  • Georgetown University Hospital - General Internal Medicine
MEDICAL SCHOOL:
  • Cornell University Medical College - MD
Provider

Jonathan R. Strosberg, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Gastrointestinal Oncology

Print Print Physician Bio

Publications

  • Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017 May;35(15):1695-1703. Pubmedid: 28384065. Pmcid: PMC5455764.
  • Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. CURR TREAT OPTION ON. 2017 Mar;18(3):14. Pubmedid: 28286921.
  • Hamiditabar M, Ali M, Roys J, Wolin EM, OʼDorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med. 2017 Jun;42(6):436-443. Pubmedid: 28263217.
  • Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul;46(6):707-714. Pubmedid: 28609356.
  • Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017 Jul;46(6):715-731. Pubmedid: 28609357.
  • Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, Wolfgang CL, Cives M, Wong J, Wang W, Sun J, Shao C, Wang W, Tan H, Li J, Ni Q, Shen L, Chen M, He J, Chen J, Yu X. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol. 2017 Jan;35(3):274-280. Pubmedid: 27646952.
  • Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan;376(2):125-135. Pubmedid: 28076709.
  • Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep. 2017 Feb;19(2):9. Pubmedid: 28220446.
  • Strosberg J, Krenning E. 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Apr;376(14):1391-1392. Pubmedid: 28379808.
  • Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect. 2016 Sep;5(5):174-187. Pubmedid: 27582247. Pmcid: PMC5045519.
  • Yao J, Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Pacaud L, Ridolfi A, Singh S, Pavel M, Kulke M. ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S253. Pubmedid: 27969445.
  • Strosberg J, Cives M, Hwang J, Weber T, Nickerson M, Atreya C, Venook A, Kelley K, Valone T, Morse B, Coppola D, Bergsland E. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 May;23(5):411-418. Pubmedid: 27080472. Pmcid: PMC4963225.
  • Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar;387(10022):968-977. Pubmedid: 26703889.
  • Strosberg DS, Nguyen MC, Mostafavifar L, Mell H, Evans DC. Development of a Prehospital Tranexamic Acid Administration Protocol. Prehosp Emerg Care. 2016 Mar;20(4):462-466. Pubmedid: 26930273.
  • Almhanna K, Weber J, Shridhar R, Hoffe S, Strosberg J, Meredith K. Determining the optimal number of lymph nodes harvested during esophagectomy. J Gastrointest Oncol. 2016 Jun;7(3):387-394. Pubmedid: 27284471. Pmcid: PMC4880760.
  • Cives M, Soares HP, Strosberg J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol. 2016 Jul;28(4):359-366. Pubmedid: 27138571.
  • Mark J, Bush S, Glazer E, Strosberg J, Saglam O, Apte SM. Metastatic VIPoma presenting as an ovarian mass. Int J Surg Case Rep. 2016 Jan;17:167-169. Pubmedid: 26657531. Pmcid: PMC4701860.
  • Caldeira CC, Sayad D, Strosberg J, Faber C, Saouma S, Michaud T. Surgical Treatment of an Isolated Metastatic Myocardial Neuroendocrine Tumor. Ann Thorac Surg. 2016 Feb;101(2):747-749. Pubmedid: 26777929.
  • Srikumar T, Markow M, Centeno B, Hoffe S, Tao J, Fernandez H, Strosberg J, Shibata D. Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. Curr Oncol. 2016 Feb;23(1):e70-e74. Pubmedid: 26966416. Pmcid: PMC4754072.
  • Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016 Feb;118(2):382-386. Pubmedid: 26861740.
  • Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C, Berruti A, Abdel-Rahman O, Fazio N. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. Neuroendocrinology. 2016 Apr;101(4):274-288. Pubmedid: 25924937.
  • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Sep;14(3):146-153. Pubmedid: 25795047.
  • Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015 Sep;16(9):e435-e446. Pubmedid: 26370353. Pmcid: PMC5023063.
  • Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A. Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol. 2015 Oct. Pubmedid: 26523441. Pmcid: PMC4980275.
  • Halfdanarson TR, Strosberg JR. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies. Curr Clin Pharmacol. 2015 Nov;10(4):305-310. Pubmedid: 26548907.
  • Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs. 2015 May;75(8):847-858. Pubmedid: 25911185.
  • Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar;33(9):1060-1066. Pubmedid: 25605849.
  • Zhu J, Strosberg JR, Dropkin E, Strickler JH. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. J Gastrointest Cancer. 2015 Jun;46(2):166-169. Pubmedid: 25662891.
  • Morse B, Strosberg J. Congenital Anomaly Detected During Work-up of Cystic Pancreatic Lesion. Gastroenterology. 2015 Jul;149(1):33-34. Pubmedid: 26025308.
  • Jones DH, Caracciolo JT, Hodul PJ, Strosberg JR, Coppola D, Bui MM. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation. Cancer Control. 2015 Jan;22(1):102-108. Pubmedid: 25504284.
  • Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Ne. 2015 Jan;13(1):78-108. Pubmedid: 25583772.
  • Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015 Feb;21(6):1945-1955. Pubmedid: 25684964. Pmcid: PMC4323475.
  • Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015 Feb;6(1):39-44. Pubmedid: 25642336. Pmcid: PMC4294830.
  • Cives M, Kunz P, Morse B, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015 Feb;22(1):1-9. Pubmedid: 25376618. Pmcid: PMC4643672.
  • Strosberg J, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski P, Van Cutsem E, Oberg KE, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec;22(6):933-940. Pubmedid: 26373569. Pmcid: PMC4609826.
  • Strosberg J, Goldman J, Costa F, Pavel M. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Front Horm Res. 2015 Aug;44:239-247. Pubmedid: 26303716.
  • Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014 Sep;19(9):930-936. Pubmedid: 25096997. Pmcid: PMC4153451.
  • Cives M, Strosberg J. An Update on Gastroenteropancreatic Neuroendocrine Tumors. Oncology (Williston Park). 2014 Sep;28(9). Pubmedid: 25224471.
  • Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014 Sep;120(18):2814-2823. Pubmedid: 24771552.
  • Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. 2014 Nov;208(5):775-780. Pubmedid: 24997491.
  • Strosberg JR. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): Cuirrent Approaches and Future Options. Endocr Pract. 2014 Feb;20(2):167-175. Pubmedid: 24014009.
  • Saranga-Perry V, Morse B, Centeno B, Kvols L, Strosberg J. Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. Neuroendocrinology. 2014 Feb;97(4):318-321. Pubmedid: 23296364.
  • Strosberg J. Evolving treatment strategies for management of carcinoid tumors. CURR TREAT OPTION ON. 2013 Sep;14(3):374-388. Pubmedid: 23892588.
  • Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-577. Pubmedid: 23591432. Pmcid: PMC4304762.
  • Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. Gastrointest Cancer Res. 2013 May;6(3):81-85. Pubmedid: 23936548. Pmcid: PMC3737510.
  • Casciano R, Wang X, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Strosberg J, Cadiot G, Riechelmann R. International practice patterns and resource utilization in the treatment of neuroendocrine tumors. Pancreas. 2013 Mar;42(2):339-347. Pubmedid: 23357923.
  • Strosberg J, Chan J, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams TA, Regan EM, Brady R, Weber J, Campos T, Kvols L, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013 Jun;20(3):383-390. Pubmedid: 23572164. Pmcid: PMC4029434.
  • Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Gastrointest Cancer Res. 2013 Jul;6(4 Suppl 1):S10-S12. Pubmedid: 24312683. Pmcid: PMC3849907.
  • Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013 Feb;31(4):420-425. Pubmedid: 23248248.
  • Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol. 2013 Feb;40(1):120-133. Pubmedid: 23391119.
  • Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ. Metastatic type 1 gastric carcinoid: a real threat or just a myth?. World J Gastroenterol. 2013 Dec;19(46):8687-8695. Pubmedid: 24379587. Pmcid: PMC3870515.
  • Henderson-Jackson EB, Nasir A, Chen DT, Nandyala P, Djeu J, Strosberg J, Kvols L, Coppola D. Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage. Pancreas. 2013 Aug;42(6):967-970. Pubmedid: 23770713. Pmcid: PMC4644941.
  • Strosberg JR, Fisher GA, Benson AB, Malin JL, Cherepanov D, Broder MS. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas. 2013 Apr;42(3):397-404. Pubmedid: 23211372.
  • Strosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ. United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol. 2013 Apr;19(15):2348-2354. Pubmedid: 23613628. Pmcid: PMC3631986.
  • Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep;23(9):2335-2341. Pubmedid: 22317769. Pmcid: PMC4559904.
  • Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol. 2012 Sep;19(9):2932-2936. Pubmedid: 22350605.
  • Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012 Oct;18(40):5679-5687. Pubmedid: 23155307. Pmcid: PMC3484335.
  • Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology-Basel. 2012 Oct;83(3):117-127. Pubmedid: 22797357.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
  • Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol. 2012 May;23(5):1335-1340. Pubmedid: 21994214. Pmcid: PMC3493136.
  • Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun;10(6):724-764. Pubmedid: 22679117.
  • Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):755-773. Pubmedid: 23582917.
  • Metz DC, Choi J, Strosberg J, Heaney AP, Howden CW, Klimstra D, Yao JC. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):306-313. Pubmedid: 22760514.
  • Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, Kvols LK. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012 Aug;256(2):321-325. Pubmedid: 22415420.
  • Henderson-Jackson EB, Helm J, Strosberg J, Nasir NA, Yeatman TJ, Kvols LK, Coppola D, Nasir A. Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. Anticancer Res. 2011 Sep;31(9):2957-2962. Pubmedid: 21868544.
  • Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011 May;40(4):627-633. Pubmedid: 21499216. Pmcid: PMC4732279.
  • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011 Jun;29(17):2350-2356. Pubmedid: 21519015. Pmcid: PMC3107750.
  • Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Jan;117(2):268-275. Pubmedid: 20824724. Pmcid: PMC4665634.
  • Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011 Dec;31(12):4387-4392. Pubmedid: 22199303.
  • Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011 Aug;29(22):3044-3049. Pubmedid: 21709192.
  • Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control. 2011 Apr;18(2):127-137. Pubmedid: 21451455.
  • Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2010 Mar;89(4):471-476. Pubmedid: 19174605.
  • Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010 Jun;16(24):2963-2970. Pubmedid: 20572298. Pmcid: PMC2890935.
  • Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?. Gastrointest Endosc. 2010 Feb;71(2):235-240. Pubmedid: 20003971.
  • Ghayouri M, Boulware D, Nasir A, Strosberg J, Kvols L, Coppola D. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 2010 Dec;30(12):5063-5067. Pubmedid: 21187491.
  • Phan AT, Oberg K, Choi J, Harrison LH, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ. NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus). Pancreas. 2010 Aug;39(6):784-798. Pubmedid: 20664476.
  • Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug;39(6):799-800. Pubmedid: 20664477. Pmcid: PMC3100733.
  • Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB, Pommier RF. The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum. Pancreas. 2010 Aug;39(6):767-774. Pubmedid: 20664474.
  • Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009 Sep;40(9):1262-1268. Pubmedid: 19368957.
  • Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Ne. 2009 Jul;7(7):712-747. Pubmedid: 19635226.
  • Strosberg JR, Hammer GD, Doherty GM. Management of adrenocortical carcinoma. J Natl Compr Canc Netw. 2009 Jul;7(7):752-758. Pubmedid: 19635227.
  • Kvols LK, Turaga KK, Strosberg J, Choi J. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Netw. 2009 Jul;7(7):765-772. Pubmedid: 19635229.
  • Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 2009 Apr;38(3):255-258. Pubmedid: 19066493.
  • Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated. Cancer Control. 2008 Oct;15(4):314-321. Pubmedid: 18813199.
  • Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008 May;2(3):113-125. Pubmedid: 19259290. Pmcid: PMC2633071.
  • Nasir A, Gardner N, Strosberg J, Ahmad N, Choi J, Malafa M, Coppola D, Kwekkeboom D, Teunissen J, Kvols L. Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. Pancreas. 2008 Apr;36(3):309-313. Pubmedid: 18362846.
  • Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology. 2007 Sep;85(4):216-220. Pubmedid: 17541257.
  • Strosberg J, Nasir A, Cragun J, Gardner N, Kvols L. Metastatic carcinoid tumor to the ovary: A clinicopathologic analysis of seventeen cases. Gynecol Oncol. 2007 Jul;106(1):65-8. Pubmedid: 17475313.
  • Strosberg J, Kvols L. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs. 2007 Feb;16(2):219-224. Pubmedid: 17243941.
  • Strosberg JR, Shibata D, Kvols LK. Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. Can J Gastroenterol. 2007 Feb;21(2):113-115. Pubmedid: 17299616. Pmcid: PMC2657671.
  • Strosberg J, Hoffe S, Hazelton T, Kvols L. External beam irradiation of myocardial carcinoid metastases: a case report. J Med Case Rep. 2007;1:95. Pubmedid: 17880715. Pmcid: PMC2040153.
  • Nasir A, Stridsberg M, Strosberg J, Su P, Livingston S, Malik H, Kelley ST, Centeno B, Coppola D, Malafa M, Yeatman T, Kvols L. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control. 2006 Jan;13(1):52-60. Pubmedid: 16508627.
  • Strosberg J, Choi J, Cantor A, Kvols L. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006 Jan;13(1):72-78. Pubmedid: 16508629.
  • Osborne D, Zervos E, Strosberg J, Boe B, Malafa M, Rosemurgy A, Yeatman TJ, Carey L, Duhaine L, Kvols L. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006 Apr;13(4):572-581. Pubmedid: 16511671.

Provider

Jonathan R. Strosberg, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Gastrointestinal Oncology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 18141
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Condition: Gastrointestinal Tumor
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
Open

CLINICAL TRIAL 18756
The Clinical Utility of a Blood-Based Multitranscriptome Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Condition: Gastrointestinal Tumor
Intervention: Not Applicable
Open

CLINICAL TRIAL 18675
Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil; CPT-11 (irinotecan); Camptosar (irinotecan); Oxaliplatin; eloxatin (Oxaliplatin); irinotecan; leucovorin
Open

CLINICAL TRIAL 18561
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19063
An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment
Condition: Gastrointestinal Tumor
Intervention: PDR001
Open

CLINICAL TRIAL 18684
A Phase II Investigator Sponsored Study of Nivolumab in Patients with Advanced Refractory Biliary Tract Cancers
Condition: Gastrointestinal Tumor
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 18422
Molecular Analysis for Therapy Choice (MATCH)
Condition: Multiple
Intervention: AZD9291 (Osimertinib); Ado-Trastuzumab emtansine; Afatinib; BIBW 2992 (Afatinib); Crizotinib; Defactinib (VS-6063); GDC-0032 (Taselisib); GSK1120212 (Trametinib); GSK2118436 (dabrafenib); Sunitinib Malate (SU011248); Taselisib; Trametinib; VS-6063; Xalkori (Crizotinib); dabrafenib
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 18739
A Phase 1 Dose Escalation And Cohort Expansion Study Of ERY974, AN ANTI-GLYPICAN 3 (GPC3)/CD3 Bispecific Antibody, In Patients With Advanced Solid Tumors
Condition: Gastrointestinal Tumor
Intervention: ERY974
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18941
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Condition: Gastrointestinal Tumor
Intervention: FOLFIRINOX; FOLFOX
Open

CLINICAL TRIAL 18521
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications
Condition: Multiple Myeloma
Intervention: Abiraterone acetate; Dexamethasone; KPT-8602; Zytiga (Abiraterone acetate)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Jonathan R. Strosberg, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Gastrointestinal Oncology

Print Print Physician Bio